12183272.txt 0 efficacies   quinupristindalfopristin combined   vancomycin   vitro     experimental endocarditis due   methicillinresistant staphylococcus aureus   relation   crossresistance   macrolides lincosamides   streptogramin b type antibiotics
12183272.txt 1   beneficial effect     combination   quinupristindalfopristin   vancomycin was observed against two methicillinresistant strains   staphylococcus aureus harboring     harboring   ermc gene   codes   constitutive macrolide lincosamide   streptogramin b resistance   beneficial effect was observed   timekill studies       drugs were used   inhibitory concentrations       rabbit model   endocarditis       combination was highly bactericidal     active than monotherapies
12183272.txt 2 
12183272.txt 3 methicillinresistant staphylococcus aureus mrsa represents   major cause   nosocomial infection   glycopeptides remain   standard therapy     treatment   systemic infections due   such strains however   emergence   mrsa strains   intermediate susceptibilities   glycopeptides  emphasizes   need   new therapeutic options   may include vancomycin   combination   another antibiotic quinupristindalfopristin q    an injectable streptogramin   combines   type   streptogramin dalfopristin     type b streptogramin quinupristin   combination   quinupristin   dalfopristin   synergistic      active   vitro against mrsa  however most strains   mrsa   cross resistant   macrolide lincosamide   streptogramin b mlsbtype antibiotics   methylation     ribosomal target   expression   mlsb resistance     frequently constitutive than inducible   mrsa  when     constitutive strains   resistant   quinupristin   remain susceptible   q  although   bactericidal activity   q    reduced   vitro     vivo  therefore   use   q    combination   another antibiotic might   required     treatment   severe infections due   strains resistant   quinupristin   order   increase   bactericidal activity     prevent   emergence   resistance   vivo since lorian et al  have shown   q      subinhibitory dose produced thickening     cell wall   was suggested     positive interaction could   observed between q    cell wallactive agents indeed   synergistic interaction has previously been reported between q    betalactams   vitro     vivo    combination   q    vancomycin against strains   mrsa might therefore     clinical interest   order   increase   bactericidal activity   q      decrease   risk   emergence   resistance   both antibiotics since strains resistant   q  have been selected   vivo  moreover studies done   vitro      an infected fibrin clot model study  suggested   benefit     combination however   susceptibilities     study strains   mlsb antibiotics were   mentioned two mrsa strains were evaluated     study hm1054   clinical strain     susceptible   quinupristin   hm1054r   strain     resistant   quinupristin     was obtained   conjugative transfer   hm1054     ermc gene   codes   mlsb resistance    two strains remained susceptible   q  mic 1 mugml whatever their profile   resistance   mlsb antibiotics quinupristin mics 8 mugml   hm1054   64 mugml   hm1054r   dalfopristin   vancomycin mics     two strains were 4   1 mugml respectively brain heart infusion bhi agar   broth difco detroit mich were used     experiments quinupristin dalfopristin   q  were     aventis vitry sur seine france   vancomycin was   lilly saintcloud france timekill studies were performed   overnight cultures diluted   fresh bhi broth   yield an inoculum   106 cfuml antibiotics were used   concentrations achievable   human   rabbit sera  q  was used   concentrations   1   4 mugml   vancomycin was used   concentrations   1 8   32 mugml after 0 3 6   24 h   incubation   37c serial dilutions   100mul samples were subcultured   incubated 24 h   37c before   numbers   cfu were counted bactericidal activity was defined     decrease     original inoculum     least 3 log10 cfuml aortic endocarditis was induced   rabbits   described previously  twentyfour hours after catheter insertion each rabbit was inoculated intravenously   1 x 106   5 x 106 cfu   s aureus   1 ml   sterile saline untreated rabbits were killed     start   therapy   served   control animals   studies   strain hm1054   killing   control animals     start   therapy were performed 48 h after bacterial inoculation   studies   strain hm1054r   delay resulted   an extremely high concentration   bacteria   vegetations     death   almost 80     rabbits before therapy was given therefore   studies     strain   killing   control animals     start   therapy were performed 36 h after inoculation     bacteria   resulted   comparable vegetation weights   bacterial concentrations   vegetations     rabbits inoculated     two strains    animals were treated intramuscularly   4 days   one     following regimens q    30 mgkg   body weight every 8 h vancomycin   50 mgkg every 8 h     combination   q    vancomycin   were injected   two different sites   q  dosing regimen provided areas under   curve   quinupristin   dalfopristin comparable   those achieved   humans after intravenous injection   75 mg   q kg    vancomycin regimen produced peak 40  8 mugml   trough 12  5 mugml levels   serum comparable   those recommended   humans   severe infections    animals were killed 8 h after   last antibiotic injection   described previously  vegetation homogenates were serially diluted   plated   agar   count   bacteria surviving after 24 h   incubation   detect resistant mutants vegetation homogenates were also plated   agar containing two   fourfold   mic   q    vancomycin   comparisons     treatment effects were performed   nonparametric oneway analysis   rank scores   several independent samples   kruskalwallis test followed     mannwhitney test   study differences between   means among   treatments     given strain   proportions   sterile rabbits were compared     fisher exact test q      concentration   4 mugml   vancomycin     concentration   8 mugml were bactericidal against both strains fig     however   bactericidal activity   q  against hm1054r was less than   against hm1054 reductions   30   49 log10 cfuml after 24 h   incubation respectively   combination   q    vancomycin     low concentration 1 mugml was bactericidal against hm1054 producing   reduction   39 log10 cfuml after 24 h   incubation whereas treatment   q  alone achieved   reduction   only 15 log10 cfuml   treatment   vancomycin alone resulted   bacterial regrowth    combination   q    vancomycin   1 mugml did   achieve bactericidal activity against hm1054r   reduction   24 log10 cfuml after 24 h   incubation   was   active than monotherapies   shown     reduction   07 log10 cfuml   q  after 24 h   incubation   bacterial regrowth   vancomycin after 24 h   incubation    combination did   add any benefit     monotherapies against   two strains when concentrations   q    vancomycin higher than 1 mugml were used     combination data   shown  fig 1  timekill experiments     activities   q    one   four times   mic qd1   qd4 respectively   vancomycin   one   eight times   mic vm1   vm8 respectively against s aureus timekill experiments     activities   q    one   four times   mic qd1   qd4 respectively   vancomycin   one   eight times   mic vm1   vm8 respectively against s aureus hm1054     s aureus hm1054r b   mics   q    vancomycin     two strains were each 1 mugml   activities     different antibiotic regimens against experimental endocarditis   shown   table  q    vancomycin alone were bactericidal against hm1054   displayed similar activities   combination   q    vancomycin was highly bactericidal     reduction   82 log10 cfug   vegetation compared     counts     controls p  0001   was significantly   active than vancomycin   q  alone p  005   addition   combination sterilized 9   10 animals 90 whereas   monotherapies sterilized 2   20 animals 10 p  0001 table 1  activities   vancomycin q    their combination against two strains   s aureus susceptible hm1054   resistant hm1054r   quinupristin after 4 days   treatment   rabbit endocarditis q    vancomycin were similarly active against hm1054r   determined     reduction   growth compared     growth     controls although q  did   achieve bactericidal activity   vivo   combination   q    vancomycin was highly bactericidal allowing   significant reduction   55 log10 cfug   vegetation compared     control growth p  0001   combination was   active than q    vancomycin p  005   sterilized 5   13 animals 38 whereas   monotherapies sterilized 1   22 rabbits 45 p  005   subpopulation   reduced susceptibility   q    vancomycin was detected   vivo regardless     infecting strain     regimen used     present work   report     combination   q    vancomycin     active than monotherapies   vivo     severe model   infection due   s aureus strains     without   constitutive mlsb resistance phenotype   terms   bactericidal activity     rate   sterilization   result correlated   those obtained     vitro timekill studies nevertheless       major importance   underline   fact     benefit was observed   vitro only   low concentrations   q    vancomycin eg concentrations   may   achieved   deep foci   infection such   cardiac vegetations       concentrations   q  greater than   mic     previously demonstrated     penetration   quinupristin into vegetations   homogeneous whereas dalfopristin showed   decreased concentration gradient between   periphery     core     vegetation    result could explain why   addition   vancomycin   q  might allow an increased effect against both strains   bacteria localized     core     vegetation however even     benefit     effect     combination was similar against   two strains   vivo   antibacterial effect     combination was less pronounced against hm1054r than against hm1054 since both q    vancomycin were less active against hm1054r than against hm1054   result was expected   q     was   expected   vancomycin   greater virulence   hm1054r may explain     vivo phenotypic tolerance observed   vancomycin   others have described previously 
12183272.txt 4 
